Company

Bank

Analyst

Coverage

Opinion

Wk chg

10/28 cls

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)

Ladenburg Thalmann

Juan Sanchez

Upgrade

Buy (from neutral)

8%

$14.64

Sanchez reiterated an $18 target. He noted AMAG could end 1Q12 with $230M in cash and the current valuation of $287M would assign a technology value of $50-$60M, which he believes is low. Earlier this month, AMAG terminated a proposed merger with cancer company Allos Therapeutics Inc. (NASDAQ:ALTH) after AMAG shareholders voted against the deal (see BioCentury, Oct. 24). AMAG markets Feraheme ferumoxytol in the U.S. to treat iron deficiency anemia in patients with chronic kidney disease (CKD).

Biogen Idec Inc. (NASDAQ:BIIB)

Baird

Christopher Raymond

Price target

Neutral

9%

$118.72